NGM Biopharmaceuticals, a Phase 2 biotech developing therapies for NASH and Type 2 Diabetes, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2007 and booked $80 million in collaboration revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol NGM. NGM Biopharmaceuticals filed confidentially on August 10, 2018. Goldman Sachs, Citi and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
